Article

Exploration of natural product database for the identification of potent inhibitor against IDH2 mutational variants for glioma therapy

2022-07-26

Abstract excerpt

<title>Abstract</title> <p>Mutation in Isocitrate dehydrogenase 2 (mIDH2) is an oncogenic driver prevalently reported in various cancer types including gliomas. To date, enasidenib is the only FDA-approved drug widely used as a mIDH2 (R140Q) inhibitor. However, dose-limiting toxicity and modest brain penetrating capability restrict its use as a plausible mIDH2 inhibitor. Furthermore, secondary site mutations (Q31...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 75719dc6-e6b1-57d4-91a5-e1be101fa583
DOI: 10.21203/rs.3.rs-1644185/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Exploration of natural product database for the identification of potent inhibitor against IDH2 mutational variants for glioma therapyDOI 10.21203/rs.3.rs-1644185/v1Read

Exploration of natural product database for the identification of potent inhibitor against IDH2 mutational variants for glioma therapy.Semantic proximity Read

In-silico lead identification of the pan-mutant IDH1 and IDH2 inhibitors to target glioblastoma.Semantic proximity Read

Steroids from Ganoderma sinense as new natural inhibitors of cancer-associated mutant IDH1.Semantic proximity Read

Molecular modeling studies to discover novel mIDH2 inhibitors with high selectivity for the primary and secondary mutants.Semantic proximity Read

Discovery of novel natural-product-derived mutant isocitrate dehydrogenases 1 inhibitors: Structure-based virtual screening, biological evaluation and structure-activity relationship study.Semantic proximity Read

Discovery of novel enasidenib analogues targeting inhibition of mutant isocitrate dehydrogenase 2 as antileukaemic agents.Semantic proximity Read

Computational study on novel natural compound inhibitor targeting IDH1_R132H.Semantic proximity Read

Identification of novel allosteric inhibitors of mutant isocitrate dehydrogenase 1 by cross docking-based virtual screening.Semantic proximity Read

Challenges for the development of mutant isocitrate dehydrogenases 1 inhibitors to treat glioma.Semantic proximity Read

Discovery and structure-activity-relationship study of novel conformationally restricted indane analogues for mutant isocitric dehydrogenase 1 (IDH1) inhibitors.Semantic proximity Read

Design, synthesis and biological activity of 3-pyrazine-2-yl-oxazolidin-2-ones as novel, potent and selective inhibitors of mutant isocitrate dehydrogenase 1.Semantic proximity Read

Rational Computational Approaches in Drug Discovery: Potential Inhibitors for Allosteric Regulation of Mutant Isocitrate Dehydrogenase-1 Enzyme in Cancers.Semantic proximity Read